A new biotech buoyed by Beam Therapeutics is taking flight, focused on RNA-based medicines. Orbital Therapeutics is launching with an undisclosed amount of money from top investors including a16z and Arch.

Perhaps the writing was on the wall for Metacrine. It was back in October 2021 that the company’s asset MET642 failed a trial in nonalcoholic steatohepatitis, setting in motion a train of events that would lead to firing half its workforce and, ultimately, its acquisition.

BioVie has drummed up investor enthusiasm for its Alzheimer’s disease prospect NE3107, reporting data from an investigator-initiated phase 2 clinical trial that sparked a 39% increase in its share price.

Ionis Pharmaceuticals has dropped more data on its AstraZeneca-partnered treatment for hereditary transthyretin-mediated amyloid polyneuropathy, shedding a little more light on how the antisense candidate matches up to Alnylam’s incumbents.

Brickell Biotech is shedding its old name to pursue Fresh Tracks, rebranding in efforts to represent a potential evolution into a clinical-stage pharmaceutical company.

At this year’s ESMO meeting, Merck is presenting a series of Keytruda failures on top of a closely watched trial win of its drug in collaboration with Seagen and Astellas' Padcev. We catch up with SVB Securities analyst Daina Graybosch, Ph.D., to walk through those important trials, what to look for in the data and their implications.

Colorado-based Flagship Biosciences, which focuses on spatial biology and biomarker analytics services, acquired Interpace Biosciences’ Pharma Solutions (IPS) division for an undisclosed price.

The Muscular Dystrophy Association (MDA) is running its new #30DaysofStrength campaign in September to raise awareness for MDA’s mission to support families across the U.S. living with muscular dystrophy, ALS and other neuromuscular diseases.

The European Commission said Illumina chose poorly when it decided to move forward with its $8 billion deal for the cancer test developer Grail.

This week on "Podnosis," we talk about the changing landscape in the femtech sector after the Dobbs decision. We also chat about health policy issues that impact underserved patient populations.

The trouble seemingly never ends for Philips’ beleaguered Respironics division.

Velocity Clinical Research extended its buying tear with the acquisition of U.S.-based MedPharmics for an undisclosed price, bringing to 40 the number of clinical trial sites the CRO has that span 19 U.S. states and Europe.

How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation

ZS helps life sciences companies shape the future of medicine by turning healthcare data into transformative insights. Discover the power of R&D innovation

Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens.

This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series).

TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases.

Improve your congress competitive intelligence and cut down costs by 50%

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.